Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 2ndmail - Not true

2ndmail - Not true

posted on Dec 19, 2007 11:03AM

Turley became CEO on June 5.  Closing share price was .49/sh.  Since then, we've hit a high of .94, almost a double, and we're trading nearly 35% higher even though we're off the high.  Perhaps Turley deserves some criticism for his PR skills, but he hasn't done anything wrong to date IMO, and more than likely has done almost everything right.

Some of the PR issues are a function of the master agreement with TPL that he inherited.  Some are just poor PR moves IMO.

Aside from that, what moves has he made that you can legitamately criticize in the short time he's been CEO.  Retiring the warrants?  Continuing the share buyback?  Suspending the dividend to instead pursue M&A?  Increased share price?  Resolution of Litigation?

Maybe not exactly the way we want things to go information wise, but the fundamental moves are hard to assail IMO.


Dec 19, 2007 11:47AM
5
Dec 19, 2007 12:09PM

Dec 19, 2007 12:25PM

Dec 19, 2007 12:49PM
1
Dec 19, 2007 01:05PM

Dec 19, 2007 02:26PM
Share
New Message
Please login to post a reply